Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analyses of iron deprived NK92 cells with deferoxamine or PPMX-T003

ABSTRACT: This work aims to detect the differentially expressed proteins between transferrin receptor 1 inhibition and iron chelation in a natural killer cell lymphoma-derived cell line NK92. Cells were treated with 500 μM deferoxamine or 10 μg/mL PPMX-T003 (an anti-transferrin receptor 1 inhibitory antibody) for 24 hours and lysed with RIPA buffer supplied with a proteasome inhibitor cocktail and a phosphatase inhibitor.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Ryo Yanagiya

PROVIDER: PXD059223 | JPOST Repository | Fri Jul 04 00:00:00 BST 2025

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	Sample_03_Slot2-1_1_25063.d.zip	Other
	Sample_03_Slot2-1_1_25517.d.zip	Other
	Sample_04_Slot2-2_1_25066.d.zip	Other
	Sample_05_Slot2-2_1_25523.d.zip	Other
	Sample_05_Slot2-5_1_25806.d.zip	Other

Items per page:

1 - 5 of 11

Publications

Revised model for cell cycle regulation by iron: differential roles between transferrin and ferritin.

Yanagiya Ryo R Kato Hiroko H Ninomiya Akinori A Ueno Masaya M Kanamori Akane A Miyatake Yuji Y Oka Masahiro M Ishii Keisuke K Matsuura Tadashi T Nakagawa So S Hirao Atsushi A Onizuka Makoto M Kotani Ai A

Redox biology 20250611

Iron is essential for neoplasms including natural killer (NK) cell lymphoma, and mainly supplemented by transferrin and stored by ferritin. Although accumulating studies had demonstrated that iron chelation arrests cell cycle progression at G1 phase, our previous studies showed the induction of DNA double strand break at S phase cell cycle without G1 arrest by selective inhibition of cellular transferrin uptake, indicating that the existence of some undiscovered differences in the roles of the t ...[more]

PMID: 40527018

Similar Datasets

Transcription profiling of human MCF-7 cells treated with proteasome inhibitor MG132 and either dexamethasone or 17b-estradiol

Project description:The objective of the study was to investigate the effect of proteasome inhibition on glucocorticoid and estrogen receptor regulated gene expression. Experiment Overall Design: MCF-7 cells were treated with proteasome inhibitor (MG132), dexamethasone, 17b-estradiol or MG132 plus dexamethasone or MG132 plus 7b-estardiol. Control cells were not treated. RNA was collected from 2 biological experiments.

2008-06-20 | E-GEOD-8383 | biostudies-arrayexpress

Differentiation of DLBCL induced by HDAC inhibitors is associated with sensitization to proteasome inhibition

Project description:Epigenetic modifying enzymes are commonly mutated in diffuse large B cell lymphoma (DLBCL), suggesting that epigenetic regulation is an important factor in DLBCL pathogenesis and a potential target for therapy. We developed resistant cell lines to histone deacetylase inhibitors (HDACi), one such epigenetic therapy, in order to define mechanisms of response and resistance. Strikingly, using gene expression and metabolic profiling, we found that development of HDACi resistance was associated with differentiation toward a plasmablast-like phenotype. Differentiation correlated with decreased B cell receptor signaling, increased ER stress and activation of the unfolded protein response, and increased sensitivity to proteasome inhibitors. Importantly, we found evidence of differentiation in lymphoma biopsies from patients treated with HDACi. Together, these data show, for the first time, that HDACi are differentiating agents in lymphoma and may be used to prime DLBCL for targeted therapy including proteasome inhibitors. Gene expression in DLBCL cells from tumor biopsies after 15 days panobinostat therapy

2016-08-01 | E-GEOD-59308 | biostudies-arrayexpress

plasmaLAG3

Project description:LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells

| PRJEB22138 | ENA

Transcriptome analysis of NK92 treated with deferoxamine or PPMX-T003

Project description:Although several types of iron deprivators are available in laboratory, the differences of them in transcriptome alterations remains unclear. In this study, we performed RNA-seq analysis of NK92 cells treated with deferoxamine (DFO; an iron chelator) and PPMX-T003 (an anti-transferrin receptor 1 inhibitory antibody) to investigate the differences in transcriptomic alterations between them.

2025-06-25 | GSE284968 | GEO

Increased Protein Processing Gene Signature in HDACi-resistant cells predicts response to proteasome inhibitors.

Project description:Epigenetic modifying enzymes are commonly mutated in diffuse large B cell lymphoma (DLBCL). Importantly, genetics abnormalities lead to inactivation of HAT, which tilt the balance in favor of decreased protein acetylation in DLBCL cells. This suggests that protein acetylation regulation is an important factor in DLBCL pathogenesis and a potential target for therapy. We developed resistant cell lines to the histone deacetylase inhibitor (HDACi) vorinostat, in order to better define molecular mechanisms of action of HDACi in lymphoma cells. We found that cells resistant to HDACi have increased protein synthesis and proteasomal degradation. Additionally, cells resistant to HDACi have acquired increased susceptibility to proteasome inhibitors and this correlates with activation of the unfolded protein response. Importantly, using transcriptional signatures found in our resistant lymphoma cell line model, we show that tumors from DLBCL patients treated but unresponsive to HDACi therapy undergo similar changes. Together, these data show, for the first time, that HDACi may be used to prime DLBCL for targeted therapy including proteasome inhibitors. Gene expression in U937 cells after 12h exposure to 2ÂµM vorinostat and after development of resistance to 2 ÂµM vorinostat, with and without vorinostat in the media.

2016-06-01 | E-GEOD-58421 | biostudies-arrayexpress

Differentiation of DLBCL induced by HDAC inhibitors is associated with sensitization to proteasome inhibition

2016-08-01 | GSE59308 | GEO

Increased Protein Processing Gene Signature in HDACi-resistant cells predicts response to proteasome inhibitors.

2016-06-01 | GSE58421 | GEO

Gene expression in CD30+ L540 cell line induced by different anti-CD30 antibodies that bind to different epitopes

Project description:CD30 receptor (TNFRSF8) is highly expressed in some types of lymphoma. Therefore, CD30 is successfully used as a target for antibody-drug conjugate to treat CD30+ lymphoma. In this study, we compared gene expression profiles induced in CD30+ L540 cell line by treating CD30 natural ligand or anti-CD30 antibodies against different epitopes.

2025-08-10 | GSE67794 | GEO

Homo sapiens

Project description:b-AP15, a novel proteasome inhibitor

| PRJNA130031 | ENA

ApoE4 disrupts intracellular trafficking and iron homeostasis in an improved iPSC-based model of human brain endothelial cells [bulk RNA-seq]

Project description:Transferrin receptor in brain endothelial cells can deliver therapeutic antibodies to the brain via transcytosis across the blood-brain barrier. Whether receptor transport remains intact in Alzheimer’s disease is still a major open question. Here, we investigated whether apolipoprotein E4 (ApoE4), the major genetic risk factor for Alzheimer’s disease, altered intracellular transport in human brain endothelial cells. To achieve this, we first developed an optimized protocol for induced pluripotent stem cells based on a defined chemical cocktail and extracellular-matrix support to differentiate brain endothelial cells (iCE-BECs). Multi-omic profiling and functional transport assays showed that iCE-BECs have a brain endothelial gene signature and recapitulate receptor-mediated transcytosis of a clinically validated BrainshuttleTM antibody against transferrin receptor. Engineered iCE-BECs homozygous for ApoE4 had altered spatiotemporal organization of early endosomes, increased transferrin receptor expression and reduced cytoplasmic iron. Our data revealed that ApoE4 can impact intracellular transport and iron homeostasis at the BBB in a cell-autonomous manner. This finding could be relevant for the brain delivery of therapeutic antibodies for Alzheimer’s disease.

2025-08-09 | GSE296358 | GEO